Parminder P. Singh, MD, FACC
My Biography
Dr. Singh is a board-certified specialist in Interventional and Structural Cardiology, Cardiovascular Diseases, and Internal Medicine. He earned his medical degree from Government Medical College in Amritsar, India, before completing his Internal Medicine residency at Wayne State University – Detroit Medical Center in Detroit, Michigan. He further specialized with a Geriatrics fellowship at the University of Michigan in Ann Arbor, followed by a Cardiovascular Diseases fellowship at Wayne State University – Detroit Medical Center. After spending a few years in private practice in Bangor, Maine, he pursued an Interventional Cardiology fellowship at Albany Medical Center and Heart Institute.
Dr. Singh holds board certifications in Interventional Cardiology and Echocardiography from the American Board of Echocardiography, as well as a certification in Nuclear Cardiology from the Certification Board of Nuclear Cardiology. He currently serves as the Nuclear Medical Director of the CT/PET program at the Heart and Vascular Center of Arizona, a state-of-the-art imaging technology for the non-invasive diagnosis of Coronary Artery Disease.
Dr. Singh’s expertise spans Structural Heart Disease, including minimally invasive procedures such as Transcatheter Aortic Valve Replacement (TAVR), Watchman device implantation, PFO/ASD closure, Carotid stenting, and complex high-risk coronary interventions with LV assist devices. He is also highly skilled in complex endovascular procedures, including Endo-luminal Graft closure for Abdominal Aortic Aneurysms, Iliac, femoral, and infra-popliteal peripheral vascular interventions. A leader in cutting-edge technologies, he has played a pivotal role in shock wave lithotripsy and laser atherectomy for both coronary and peripheral vascular procedures. Additionally, he is a leading implanter of leadless pacemakers in Arizona and has performed numerous mechanical pulmonary artery and venous thrombectomies, as well as IVC filter placements and removals.
Beyond his clinical practice, Dr. Singh holds several leadership positions. He currently serves as the President of the Heart and Vascular Center of Arizona and the Medical Director of the Cardiac Catheterization Laboratory at Banner Estrella Hospital. Throughout his distinguished career, he has been actively involved in clinical research trials and has been recognized as a Top Doctor by Phoenix Magazine.He is also currently Clinical Professor of Medicine,University of Arizona School of Medicine.
- DIABETES AND CARDIOVASCULAR DISEASES, SINGH P, KAUR J, SOWERS JR, AMERICAN JOURNAL OF THERPEUTICS 2002: NOV-DEC; 9(6) 510-5 – This was an extensive review article on the impact of Diabetes Mellitus on the Cardiovascular diseases. Due to increasing obesity in the US, the incidence of Diabetes Mellitus continues to increase leading on to increased cardiovascular morbidity and mortality. Both in Men and women, the leading cause of mortality is cardiovascular diseases and its implications discussed in this review article.
- CYTOMEGALOVIRUS –INDUCED GINGIVAL HYPERPLASIA, KAUR J, SINGH P, LEVINE D, CLINICAL INFECTIOUS DISEASE 2003 AUG 15; 37(4): e 44-6
- MULTIPLE MYELOMA IN THE LIVER, KAUR J, TURNER J, SINGH P, AL-KATIB, AYAD, AMERICAN JOURNAL OF HEMATOLOGY, VOL 65 ISSUE 4, DECEMBER 2000
- COCAINE INDUCED TORSADES DE POINTES IN IDIOPATHIC LONG QT SYNDROME, SINGH N, SINGH P, KHAN IA, AMERICAN JOURNAL OF THERAPEUTICS JUL-AUG 2001; 8(4) 299-302
- TUBERCULAR LIVER ABCESS, SINGH P, ARORA R, MAHAJAN DS, BATRA KS, SHARMA OP, INDIAN JOURNAL OF CLINICAL PRACTICE, FEB1995, VOL 5
- DRUG INDUCED PANCYTOPENIA, KAUR J, SINGH P, LaCHANT N, AMERICAL COLLEGE OF PHYSICIANS, MICHIGAN CHAPTER, 1999
- PROSTHETIC VALVE ENDOCARDITIS DUE TO S.MALTOPHILIA, SINGH P, BROWN PATRICIA, AMERICAN COLLEGE OF PHYSICIANS, MICHIGAN CHAPTER, 1997
- PERSISTENTLY NORMAL GLYCATED HEMOGLOBIN IN POORLY, CONTROLLED TYPE 1 DIABETES MELLITUS, KAUR J, KLEEREKOPER M, SINGH P, MAHAKALA A, AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS, 2002, ABSTRACT AND POSTER PRESENTATION
- A SIX MONTH COMPARATIVE EVALUATION OF AMLODIPINE WHICH IS (NORVASC- TOP 10 SELLING DRUG IN THE WORLD) VERSUS ENALAPRIL IN MILD TO MODERATE HYPERTENSION – ACCEPTED AND PUBLISHED AS A THESIS IN THE MD DEGREE). Parminder Singh, OP Sharma.-1994 – This was a 6 months study conducted in 1994 to compare the effect of Amlodipine well known as NORVASC from Pfizer (Among the top 5 selling medication in the World –US Sales 2.2 Billion dollars in 2003 as per IMS, a healthcare information firm—Forbes.com) comparing it with Enalapril, another drug given for hypertension (high Blood Pressure).This study revealed that Amlodipine was better than Enalapril in mild to moderate Hypertension in Indian ethnic population.
- BRIDGING STUDY : Principal Cardiology fellow Investigator for Phase 2 Multicenter-Randomized Trail Comparing outpatient Tinzaprin versus inpatient Intravenous Heparin who are getting long term warfarin therapy for invasive or surgical procedure at Harper University Hospital ( 3rd largest center out of 28 in the US).
Education & Board Certifications
Medical School
- Government Medical College in Amritsar, India
Fellowship
- Geriatrics - University of Michigan, Ann Arbor, Michigan; Cardiovascular Disease - Wayne State University-Detroit Medical Center; Interventional Cardiology - Albany Medical Center and Heart Institute
Internship / Residency
- Wayne State University – Detroit Medical Center, Detroit, Michigan
Board Certifications
- Echocardiography - American Board of Echocardiography
- Nuclear Cardiology - Certification Board of Nuclear Cardiology